(A) GL261 cells were implanted into the striatum of C57/Bl6 mice. 17 d later animals were treated with Ad-Flt3L (n = 5), Ad-TK (+GCV) (n = 6), Ad-Flt3L plus Ad-TK (+GCV) (n = 5), or saline (n = 5). Treatment with Ad-Flt3L and Ad-TK significantly improved survival when compared to saline (*, p < 0.05; Mantel log-rank test), Ad-Flt3L, or Ad-TK alone treatment groups (^, p < 0.05; Mantel log-rank test). Treatment with Ad-Flt3L, or Ad-TK alone significantly improved survival when compared to saline (*, p < 0.05; Mantel log-rank test).
(B) 7 d after treatment, tumor-bearing animals were humanely killed and HMGB1 release was assessed in the serum. Treatment of GL261 tumor-bearing animals with Ad-Flt3L and Ad-TK (+GCV) significantly increased the levels of HMGB1 in the serum when compared to tumor-bearing animals treated with saline. *, p < 0.05 versus saline (Mann-Whitney U-test).
(C) B16-F10 cells were implanted into the striatum of C57/Bl6 mice. 17 d later animals were treated with Ad-Flt3L, Ad-TK (+GCV), Ad-Flt3L plus Ad-TK (+GCV), or saline. Treatment with Ad-Flt3L and Ad-TK significantly improved survival when compared to saline (*, p < 0.05; Mantel log-rank test), Ad-Flt3L, or Ad-TK alone treatment groups (^, p < 0.05; Mantel log-rank test). Treatment with Ad-Flt3L, or Ad-TK alone, significantly improved survival when compared to saline (*, p < 0.05; Mantel log-rank test).
(D) 7 d after treatment, tumor-bearing animals were humanely killed and HMGB1 release was assessed in the serum. Treatment of B16-F10 tumor-bearing animals with Ad-Flt3L and Ad-TK (+GCV) significantly increased the levels of HMGB1 in the serum when compared to tumor-bearing animals treated with saline. *, p < 0.05 versus saline (Mann-Whitney U-test).